고려대학교 의과대학 및 의과학연구지원센터 구성원이 아닌 경우에는 본인인증을 통하여 글을 작성할 수 있습니다.
- 본인인증 후 글을 작성할 수 있습니다.
-
내 명의의 휴대전화로 비밀번호를 재설정 할 수 있습니다.
Fenofibrate Treatment as Add-on Found Effective in Preventing Cardiovascular Disease in Patients with Metabolic Syndrome 
A research team led by Dr. Sin Gon Kim professor of internal medicine and Nam Hoon Kim, professor of endocrinology and metabolism, proved that fenofibrate treatment as add-on can help prevent cardiovascular diseases in Korean patients with metabolic syndrome. For the first time in the world, state-based big data were utilized to show the efficacy of fenofibrate in patients with metabolic syndrome.
In a number of large-scale clinical trials, statin, an agent mainly used to control LDL cholesterol, has been proven effective in reducing the risk of heart attack, stroke, and even death from heart disease. To be specific, statins can reduce the risk of cardiovascular disease by 20~30% but they focus on exclusively reducing the LDL cholesterol. So there came the necessity to have a treatment to control triglycerides and HDL cholesterol.
Fenofibrate, a peroxisome proliferator activated receptor-α agonist, has been suggested as an important treatment option in the reduction of residual cardiovascular risk as it can improve atheromatous sclerosis as well as blood lipid levels. However, large randomized clinical trials of fenofibrate, including the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial and the Action to Control Cardiovascular Risk in Diabetes (ACCORD)-Lipid trial failed to show a reduction in major cardiovascular events in populations with type II diabetes.
Given that those failed studies were conduced in the Western patients whose triglyceride level was not that high and they had type II diabetes, it was suggested that the result might be different if it was used in the Korean population who were more susceptible to hypertriglyceridaemia and metabolic syndrome than Western counterparts.
The Korean National Health Insurance Service-Health Screening Cohort (2002-2015) were used to identify 29,771 adults with metabolic syndrome receiving statin treatment (HMG-CoA reductase) and they were divided into one group that received fenofibrate in addition to the statin and the other group who did not and then both were followed-up for about 30 months on the average. The risk of heart attack, stroke, and death from heart disease was reduced by 26% in the combined treatment group. Such benefit was even greater in those patients with high triglycerides and low HDL cholesterol.
This study indicates that people with uncontrolled triglyceride and HDL cholesterol on statin may benefit from fibrate. The national data-based study shed a new light on the value of fibrate, a dyslipidaemia therapy whose value has been underestimated.
The previous studies were mainly conducted in Western populations, which limits generalisability of the results to Koreans. More studies of this kind should be conducted in order to practice evidence-based medicine in a way that it can fully benefit the Korean population.
pubmed link: https://www.bmj.com/content/366/bmj.l5125
BMJ 2019; 366 doi: https://doi.org/10.1136/bmj.l5125
Ground-breaking Ceremony for Cheongdam Campus
Starting from Anonymous Donation, Spirit of Share is Planted to Nurture Future of Medicine
Advanced Facilities for Education and Research Leading Innovation-based Growth
Hub for Healthcare in the Era of Digital Convergence
On September 24, 2019, Korean University Medicine had a ground-breaking ceremony to build the Cheongdam Campus, which will function as the major hub facilities for the future medicine.
The construction of Cheongdam Campus, digital healthcare facilities that provide specialized care service along with convergence education, is planned to be completed by late July 2021. Once completed, it is expected to serve as an outpost enabling the Korean University Medicine to achieve its vision of ‘Create the future medicine and connect the world’ as proclaimed last year.
The campus is to be built on the land donated in April 2007 by an anonymous benefactor, who said that it was the will of his or her mother. Located on 411, Dosandaero, Gangnam-gu, Seoul, the 10-story building will house a specialized care center, the KU Medicine Media lab, the Digital twin Data Mining Center, a real-time Dashboard Command Center which will allow efficient operation of the three hospitals, lecture halls for international conferences and a faculty lounge.
The impaired antiviral innate response in chronic rhinosinusitis may be reversed by macrolides and glucocorticoids
A research team led by Sang Hag Lee, Professor of Otorhinolaryngology-Head & Neck Surgery, College of Medicine, Korea University, revealed the pathogenetic mechanisms in impaired antiviral innate response in chronic rhinosinusitis.
Chronic rhinosinusitis (CRS) is a heterogenous mucosal inflammation involving paranasal sinuses, with pathophysiological causes that remain unclear. An abnormal host response to infectious microorganisms like virus and bacteria has been suggested to be responsible for the persistent inflammation of the sinonasal mucosa. A high frequency of virus presence is demonstrated in nasal epithelial cells or lavage fluids of CRS patients.
Because the interferon (IFN) response of sinonasal epithelial cells, which is critical for defense against viral infection, remains unknown, the present study evaluated the expression levels of type I and III IFN and IFN-stimulated genes (ISGs) in chronic rhinosinusitis.
This study had the following key finding:
. The levels of IFN and ISGs expressed in normal sinonasal mucosa were decreased in CRS patients.
. IFN and ISGs were up-regulated in cells treated with macrolides, dexamethasone, or TLR3 agonist.
These findings provide another mechanism of impaired antiviral innate response in chronic rhinosinusitis and show the positive effects of macrolide and glucocorticoids on the treatment of chronic rhinosinusitis.
The research results were published in online version of Journal of Allergy and Clinical Immunology (Impact factor; 14.11) under the title, Decreased expression of type I (IFN-β) and III interferon (IFN-λ) and IFN-stimulated genes in chronic rhinosinusitis with and without nasal polyps.
pubmed link: https://www.ncbi.nlm.nih.gov/pubmed/31449915
J Allergy Clin Immunol. 2019 Aug 23. pii: S0091-6749(19)31096-6. doi: 10.1016/j.jaci.2019.08.010.
Scholars of 9 Countries on Medical Research and Education Attend the 3rd annual meeting of the Global Alliance of Medical Excellence at KUCM
Korea University College of Medicine (KUCM) successfully hosted the third annual meeting of the Global Alliance of Medical Excellence meeting on 26 & 27 September 2019.
Established in 2017, the Global Alliance of Medical Excellence (GAME) is a strategic international network of medical schools that share a common interest in promoting innovative medical education and undertaking impactful research. Its members include the Chinese University of Hong Kong, Monash University of Australia, Canadian University of Alberta, German University of Munich, Nagoya University of Japan, Erasmus MC of the Netherlands, Italian University of Bologna, and British University of Nottingham in addition to the Korea University College of Medicine.
At the meeting attended by more than 40 professors or deans of nine member institutions, updates on the collaborative research projects currently underway were shared along with future plans. The agenda also included introduction of research projects and educational programs of the University of Alberta Medical and Dental Schools, precision medicine of Korea, a research project on liver damage conducted in collaboration with the International Drug Injury Network, building the prevention research network, recent education on medicine, international microbiome research network, collaboration to build health management data and the research on the cohort with Lewy body risk and others. Member universities also shared research and education strategies each other and had a heated discussion on how to maintain sustainability of the GAME network.
Among others, participants showed keen interest in the presentation on the outcome of the medical student camp held in Nagoya in July as part of the Transnational Educational Initiatives (TEI) under the theme of 'Doctor's Professionalism in Disaster,' and a lecture on the current status and future of the medical education in Korea by honorary professor of Duck-Sun Ahn, vice chairman of World Federation of Medical Education (WFME).
Hong Sik Lee, Dean of Medical College said, “I am very happy that we hosted the third annual meeting of GAME and hope that our solid network consisting of nine core medical schools of the world could help take the medical education to another level.” He also added, “I believe we made a good contribution to the enhancement of international collaboration for research and we should make further efforts to present a new paradigm for medical education and come up with international standards for quality education.”
